AgingResearch.NewsJoin free

Phase 1Status unknown

Phase I Clinical Trial of a Candidate HPV Vaccine

A Phase I, First-in-human, Randomized, Observer-blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of BV601 in Healthy Adult Volunteers

Sponsor
Wuhan BravoVax Co., Ltd. (Industry)
Enrolment
40 planned
Conditions
Human Papillomavirus Infection
Interventions
Human papillomavirus (HPV) Vaccine; Placebo
Ages
adults
Registry
NCT05672966

Full record on ClinicalTrials.gov

From the registry

This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a HPV Vaccine) in healthy adult volunteers.

Primary outcomes

  • Safety in terms of solicited adverse events
  • Safety in terms of solicited systemic AEs
  • Safety in terms of dose-limiting toxicity (DLT)
  • Safety in terms of unsolicited AEs

History

  1. Study completion

  2. Primary completion

  3. Started

  4. Last registry update

  5. Registered